Telitacicept safely and effectively eased disease activity in adults with primary Sjögren’s disease, according to data from a now-complete Phase 3 clinical trial conducted in China. Because the trial met its primary goal, developer Remegen plans to ask China’s regulator, the Center for Drug Evaluation of the National Medical Products Administration, to approve the drug, according […] The post Telitacicept shows promise for primary Sjögren’s in Phase 3 trial appeared first on Sjogre...
